Steven Sunshine said he received a “curious” phone call from the Federal Trade Commission in March 2009.
The Skadden, Arps, Slate, Meagher & Flom partner was representing a generic drug company that was under investigation by the FTC for a private settlement over brand-name sleep disorder drug Provigil. But the FTC official, Sunshine recalled in court, didn’t want to talk about the probe. Rather, Sunshine said he was asked about having his client team up with another generic drug maker in order to take a run at Provigil’s market share.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
